On the mechanisms of statin-induced myopathy

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 6, 2006, Pages 529-531

  Laaksonen, Reijo ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; SIMVASTATIN; UBIQUINONE;

ARTICLE; CALCIUM TRANSPORT; CHOLESTEROL METABOLISM; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ALCOHOL INTERACTION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; EXERCISE; GENETIC DISORDER; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; MITOCHONDRIAL MYOPATHY; MYALGIA; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES;

EID: 33744523781     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.02.013     Document Type: Article

References (11)

1. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
3. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
4. Paiva H., Thelen K.M., Van Coster R., Smet J., De Paepe B., Mattila K.M., et al. High-dose statins and skeletal muscle metabolism in humans. a randomized, controlled trial. Clin Pharmacol Ther 78 (2005) 60-68
5. Bruckert E., Hayem G., Dejager S., Yau C., and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO Study. Cardiovasc Drugs Ther 19 (2006) 403-414
6. Mukhtar R.Y., and Reckless J.P. Statin-induced myositis. a commonly encountered or rare side effect?. Curr Opin Lipidol 16 (2005) 640-647
7. Hermann M., Bogsrud M.P., Molden E., Åsberg A., Mohebi B.U., Ose L., et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 79 (2006) 532-539
8. Troseid M., Henriksen O.A., and Lindal S. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. APMIS 113 (2005) 635-637
9. Morikawa S., Murakami T., Yamazaki H., Izumi A., Saito Y., Hamakubo T., et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 12 (2005) 121-131
10. Morikawa S., Takabe W., Mataki C., Wada Y., Izumi A., Saito Y., et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11 (2004) 62-72
11. Urso M.L., Clarkson P.M., Hittel D., Hoffman E.P., and Thompson P.D. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 25 (2005) 2560-2566